Environmental Assessment of Genetically Engineered Animals at CVM (FDA) Animal Biotechnology Interdisciplinary Group Center for Veterinary Medicine U.S.

Slides:



Advertisements
Similar presentations
Inadequacies in the Federal Regulation of Agricultural Biotechnology Gregory Jaffe Director, Biotechnology Project Center for Science in the Public Interest.
Advertisements

Office of New Animal Drug Evaluation Laura L. Hungerford, DVM, MPH, PhD Senior Advisor, Science and Policy, ONADE Professor, University of Maryland School.
Summary of NEPA and SEPA Coastal Engineering and Land Use Issues in North Carolina Greenville, NC January 13, 2009 Sean M. Sullivan.
Environmental Assessments Human and Animal Drugs Nancy Sager Center for Drug Evaluation and Research Food and Drug Administration.
Phenotypic Characterization Harlan Howard, PhD. Describes the animal, construct, and proposed claim Are there sequences that are likely to contain potential.
Essentials of Biology Sylvia S. Mader
Molecular Biology. It’s a Matter of Perspective The investigators who submit IBC protocols want to perform their experiments safely. The investigators.
Introduction to Regulation
Evolutionary Computation Introduction Peter Andras s.
Food Safety Assessment Kevin Greenlees, PhD, DABT Kathleen Jones, PhD.
BIOSAFETY CONCERNS IN THE CONTEXT OF BIOTECHNOLOGY. Presentation for Training Workshop for Regional Advisors Bangkok, Thailand May 2006.
Jeff Jones, DVM, PhD Animal Biotechnology Interdisciplinary Group Center for Veterinary Medicine U.S. Food and Drug Administration Regulation of Genetically.
Environmental Safety Assessment Eric Silberhorn, PhD, DABT.
FDA’s Policy for Evaluating Bioengineered Foods Jeanette Glover Glew Food and Drug Administration Center For Food Safety and Applied Nutrition September,
Background, Introduction, Statutory Authority, Introduction to Risk-Based Approach Larisa Rudenko, PhD, DABT.
INADs and Beginning the Review Process Larisa Rudenko, PhD, DABT.
Malini M. Wileman, PhD, RAC Animal Biotechnology Interdisciplinary Group Center for Veterinary Medicine U.S. Food and Drug Administration Regulation of.
Mrs. Brandi Robinson Office of New Animal Drug Evaluation Center for Veterinary Medicine Regulating Animal Drugs.
The National Environmental Policy Act (NEPA)
Durability Joseph W. (Jay) Cormier, PhD. Describes the animal, construct, and proposed claim Are there sequences that are likely to contain potential.
Pest Risk Analysis International Plant Protection Convention (IPPC)
Biosafety and recombinant DNA technology. Involves.... Experiments involving the construction or use of GMOs should be conducted after performing a biosafety.
AquaAdvantage Salmon Lisa Danielson. Outline Introduction Explanations Significance Research Question Methodology My approach Literature Review Problems.
What does the Law Have to Say About Marine Diseases? Honestly, Not Much!! Stephanie Otts Director, National Sea Grant Law Center RCN Disease Modeling Workshop.
Principles for the Oversight of Synthetic Biology- Precautionary Principle 1  “When an activity raises threats of harm to human health or the environment,
HABITAT CONSERVATION PLANNING Charles J. Randel, 1 III, Howard O. Clark, Jr., 2 Darren P. Newman, 2 and Thomas P. Dixon 3 1 Randel Wildlife Consulting,
Data Requirements for Field Release and Monitoring Jon Knight Imperial College London
RISK ASSESSMENT OF GMOs UNDER CONTAINED AND FIELD USE EXPERIMENTS Veronica O. Sinohin; Senior Science Research Specialist Ecosystems Research and Development.
Center for Veterinary Medicine (CVM) RECALLS.  21 CFR 7.40 provides guidance on the policy, procedures, and industry responsibilities for recalls. 
Nonclinical Studies Subcommittee Advisory Committee for Pharmaceutical Science CMC Issues for Screening INDs Eric B. Sheinin, Ph.D. Acting Deputy Director.
Natural Selection Developed by Charles Darwin in 1859
PREVIEW 1 ST SIX WEEKS – 5 WEEKS LONG 2 ND SIX WEEKS – 5 WEEKS LONG 3 RD SIX WEEKS – 6 WEEKS LONG 2 WEEKS OF TESTING SEMESTER ENDS BEFORE CHRISTMAS.
USDA-APHIS Plant Pest Risk Assessments Science Issues and Research Needs Biotechnology Risk Assessment Grants Program 2015 Project Director’s Meeting.
Evolution. What is evolution? A basic definition of evolution… “…evolution can be precisely defined as any change in the frequency of alleles within a.
Confronting Contamination: Biosafety Lim Li Lin, Third World Network.
Clinical Trial Review and Approval: New Regulations and their implications Siddika Mithani, Ph.D Clinical Trials & Special Access Programme Therapeutic.
Completing the NEPA Process for CatEx Projects: Part 3 to CE Closeout.
Chapter 5 Characterizing Genetic Diversity: Quantitative Variation Quantitative (metric or polygenic) characters of Most concern to conservation biology.
CP Biology Ms. Morrison. Genes and Variation  Gene pool = combined genetic information of all members of a particular population  Relative frequency.
EPA: Research Needs and Considerations for Microbial Pest Control Agents and Plant- incorporated Protectants NIFA BRAG PI Meeting, June 4, 2014 John L.
Overview of the USDA Biotechnology Risk Assessment Grants Program Deb Hamernik, PhD National Program Leader, Animal Physiology US Department of Agriculture.
Section 4.0 Human Activity Affects Biological Diversity.
Genetics and Speciation
EVOLUTION & SPECIATION. Microevolution. What is it? changes in the gene pool of a population over time which result in relatively small changes to the.
Evolution Objective: K1 - Analyze & evaluate how natural selection produces changes in a population, not individuals & describe the three types of isolation.
Codex Science-based Approach to the Safety of Foods Derived from Modern Biotechnology James H. Maryanski, Ph.D. Food and Drug Administration Center for.
Overview of Risk Assessment and Risk Management of PIPs in the U.S.
Genetically Modified Foods Beth Roberson November 19, 2004 FST 490.
Driving forces Pressure Human travelTrade of commodities State Release the environmentEscape in the environment Contaminant in commodity Stowaway in transport.
Environmental Assessment of Genetically Engineered Animals at CVM (FDA) Animal Biotechnology Interdisciplinary Group Center for Veterinary Medicine U.S.
SC.912.L Mutations 2. Genetic Recombination (sexual reproduction)
What is a phylogenetic tree? Agenda for Tuesday Nov 30 th 1.Mechanisms of Evolution notes.
Evaluating the Safety of Antimicrobial New Animal Drugs with Regard to Their Microbiological Effects on Bacteria of Human Health Concern Qualitative Antimicrobial.
DEPARTMENT OF HEALTH CENTER FOR BIOLOGICS AND HUMAN SERVICESEVALUATION and RESEARCH AND HUMAN SERVICES EVALUATION and RESEARCH Update on OCTGT Guidance.
Some common genetic engineering applications A brief overview.
Emerging Threats Program Text The Emerging Pandemic Threats Program.
CE 360Dr SaMeH1 Environmental Eng. 1 (CE 360) Associate Professor of Environmental Eng. Civil Engineering Department Engineering College Majma’ah University.
It’s a food… It’s a drug… It’s AquAdvantage Salmon! Ricardo Carvajal Hyman, Phelps & McNamara, P.C st Annual Tulane.
Mechanisms for Evolution. Populations and Evolution A population is a group of organisms that interbreed Each population shares a gene pool (the different.
Biosafety and Recombinant DNA Technology
Trade and Pest Management
National Environmental Policy Act (NEPA)
Mechanisms for Evolution
Unit 6 NEPA.
Factors that Affect the Process of Evolution
Introduction to Evolution
Darwin based his theory on his own observations and the writings of Thomas Malthus. Malthus was a British social scientist who made these observations.
Diversity of Life Species Gene pool.
Vocab #21 Mr. Addeo.
FDA Regulation of Animal Biotechnology Products
Presentation transcript:

Environmental Assessment of Genetically Engineered Animals at CVM (FDA) Animal Biotechnology Interdisciplinary Group Center for Veterinary Medicine U.S. Food and Drug Administration Evgenij A. Evdokimov, MS, PhD June 4, 2015

Major Statutes Governing Regulation of GE Animals Federal Food, Drug, and Cosmetic Act (FD&C Act) Products are regulated; not processes * GE animals are regulated under New Animal Drug Provisions of the Act * National Environmental Policy Act (NEPA) Procedural; major agency’s actions trigger NEPA assessment * Regulated article - article intended to affect the structure or function of the animal (e.g., rDNA construct)

Guidance for Industry 187* Regulated article = article intended to affect the structure or function of the animal (e.g., rDNA construct) Covers all types of GE animals All GE animals in a lineage are covered Event-based, case-by-case evaluation Enforcement discretion and approval paths New Animal Drug Application (NADA) means mandatory approval prior to marketing Post-market surveillance * eredAnimals/default.htm

Are there significant direct or indirect effects from introduction of the GE animal into the environment? Basis for satisfying NEPA requirements. Hierarchical Risk-Based Evaluation

Finding of No Significant Impact (FONSI) NEPA Process Overview Regulated Article May Significantly Affect Environmental Impact Statement (EIS) No Significant Effects Record of Decision (ROD) Environmental Assessment (EA)

Biological Containment Physical Containment Source(s) Escape or Introduction Able to Survive Impact on Target Resources in the Environment (habitats, wildlife) Dispersion Direct and Indirect Effects Accessible Environments Able to Reproduce Establishment Spread of Transgene(s) Wild Conspecifics Feral Relatives Net Fitness Geographical/ Geophysical Containment Conceptual Framework for Environmental Assessment ? ? ?

Environmental Assessment: General Risk Questions For a specific GE animal (population) containing a specific regulated article…. –What is the intent (free release or contained use)? If contained use - what is the likelihood of escape? –What is the likelihood of survival in the receiving environment? –What is the likelihood of establishment and reproduction? –What are potential consequences/effects to the environment associated with introduction/inadvertent release? Considered in context of an appropriate comparator on a case-by-case basis

Potential Environmental Hazards and Harms HazardHarm Does the rDNA construct introduce any hazardous elements into the animal (e.g., viral or mobilizable sequences, sequencing encoding pathogens or toxins, vectors) (Characterized in Molecular Characterization steps) Increased probability of new pathogenic recombinants Do introduced traits affect species fitness or adaptation (Characterized in Phenotypic Characterization) Increased probability of disruption of existing ecosystems due to establishment of a GE animal in the environment

Fitness Fitness affects survival and reproduction Net fitness components include –Juvenile and adult viability –Age at sexual maturity –Female fecundity/male fertility/mating success

Impacts Pathogen / disease transfer Genetic disturbance Resource competition Displacement Habitat destruction Predation Population changes Community/Ecosystem disruptions

Consequences of Introduction, Escape, and Dispersion Will depend largely on: Specific physical locations of production or release; Extent of containment (if applicable); –Physical/mechanical –Biological (e.g., sterility, monosex) –Geographical/geophysical (environmental conditions) –Domestication of species (ability to become feral) Mobility of species

Areas of interest Potential risks associated with introduction of GE animals into the environment that are function of the introduced trait –Longevity; –Mating behavior; –Stability of genotype and phenotype over time;

Areas of interest Do we always need containment for GE animals?Do we always need containment for GE animals? –GE terrestrial livestock intended for food use? –GE animals for population control? –GE animals receiving gene therapy treatment? What risks do we guard against?What risks do we guard against? Is gene flow a risk per se?Is gene flow a risk per se?

Questions? Contacts at CVM: Dr. Evgenij Evdokimov